TY - JOUR
T1 - Phase 2 study of 5'-DFUR for bladder and prostatic cancer
AU - Ohmori, H.
AU - Matsumura, Y.
AU - Ochi, J.
AU - Kobashi, K.
AU - Akebi, N.
AU - Saika, T.
AU - Nanba, K.
AU - Tanahashi, T.
AU - Josen, T.
AU - Nasu, Y.
AU - Saegusa, M.
AU - Ozaki, Y.
AU - Hara, M.
AU - Asahi, T.
AU - Ike, N.
AU - Tsushima, T.
AU - Mitsuhata, N.
AU - Akagi, T.
AU - Kaeda, T.
PY - 1991/1/1
Y1 - 1991/1/1
N2 - Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.
AB - Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University. 5'-DFUR was orally administered to patients at a daily dose of 800-1200 mg for more than 4 weeks. Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated. The response rate for bladder cancer was 31.7% (CFR, 1 case: PR, 12 cases), against no response with prostatic cancer. Moreover, the concentration of 5-FU in bladder tumors was confirmed to be high. Adverse reactions such as diarrhea, anorexia, and nausea were observed. Thus, 5'-DFUR seems to be useful for the treatment of bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=0025933224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025933224&partnerID=8YFLogxK
M3 - Article
C2 - 1834024
AN - SCOPUS:0025933224
VL - 18
SP - 2307
EP - 2314
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 13
ER -